菜单
About Aidea
  • 3
    3 National 13th Five-Year Plan Science and Technology Major Projects of "Major New Drug Development"
  • 2
    2 Transformation of Scientific and Technological Achievements Projects in Jiangsu Province
  • 3
    3 Key Technological Innovation Projects in Jiangsu Province
  • 30
    30 Patents
Core competitiveness
  • Core technology
    Fresh flow adsorption of urinary protein
  • Strategic program
    For solution of major diseases
  • Talent team
    For innovative R&D
  • Prospective layout
    For future commercialization
History & Honor
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • Ainuovirine Tablets was included in the national reimbursement drug list. .
  • Ainuovirine Tablets was approved for marketing.
  • Raw material of Ulinastatin won the title of "Specialized, Fined, Peculiar and Innovative Product of Jiangsu Province”.
  • The company received Provincial Special Funds for the Development of Strategic Emerging Industries of Jiangsu in 2021
  • The company won the title " Model Unit of Yangzhou 2019-2020".
  • Aidea Pharma was successfully listed on the SSE STAR Market (stock abbreviation: Aidea Pharma, stock code: 688488)
  • Ainuovirine obtained the Notification of Drug Registration Application Acceptance
  • Ulinastatin for injection obtained clinical trial approval
  • Aidea Pharma completed the shareholding reorganization and was renamed as "Jiangsu Aidea Pharmaceutical Co., Ltd.".
  • ACC008 was included into the national 13th Five-Year Plan Science and Technology Major Projects as"Major New Drug Development".
  • ACC010 obtained clinical trial approval.
  • Nanjing Accelas Pharmaceutical Technology Co., Ltd. was recognized as one of the Nanjing Antiviral Drug R&D Engineering and Technology Research Centers.
  • Ainuovirine compound tablets (ACC008) obtained the approval letter for drug clinical trial.
  • Aidea Pharma obtained the pharmaceutical GMP certificate.
  • Ainuovirine obtained the provincial special funds for enterprise innovation and achievement transformation in 2018.
  • Ainuovirine, a national first class anti-AIDS new drug, was entitled as one of the national 13th Five-Year Plan Science and Technology Major Projects of "Major New Drug Development".
  • Ainuovirine, a national first class anti-AIDS new drug, obtained the approval letter for drug clinical trial.
  • Aidea Pharma set up a Jiangsu postgraduate workstation.
  • Aidea Pharma was renamed as Jiangsu Aidea Pharmaceutical Co., Ltd.
  • Aidea Pharma obtained the strategic investments from Jiangsu Hi-Tech Investment Company, Huatai Securities and STARR.
  • Aidea Pharma has been recognized as one of the Jiangsu Enterprise Technology Centers.
  • A wholly owned acquisition of Yangzhou Xingdou Pharmaceutical, and renamed as Yangzhou Aidea Pharmaceutical Co., Ltd.
  • Crude human urinary kallidinogenase was recognized as high-tech products by Jiangsu Province in 2014.
  • Aidea Pharma has been recognized as the Human Urine Protein Engineering Technology Research Center of Jiangsu Province
  • Aidea Pharma established the enterprise academician workstation.
  • The "R&D and Industrialization Project on Fresh Flow Adsorption Technology of Active Protein and Processes for Large-scale Preparation of Ulinastatin and Albumin” obtained the provincial special fund for enterprise innovation and achievement transformation in 2013.
  • "Development of the fresh flow adsorption method for industrial-scale production of crude Ulinastatin" won the first prize of the science and technology award.
  • Establishment of the subsidiary corporation Nanjing Accelas Pharmaceutical Technology Co., Ltd.
  • Raw material of urokinase by fresh flow adsorption was recognized as high-tech products by Jiangsu Province in 2013
  • Aidea Pharma was included in the key project list of the Yangzhou Engineering and Technology Research Center in 2012.
  • Aidea Pharma was recognized as one of the Yangzhou Enterprise Technology Centers in 2012.
  • Crude Ulinastatin containing lower content of vasoactivity substances was recognized as high-tech products by Jiangsu Province in 2012
  • The crude urinary albumin was recognized as high-tech products by Jiangsu Province in 2011.
  • Aidea Pharma was awarded as "High-tech Enterprise".
  • Crude Ulinastatin was recognized as high-tech products by Jiangsu Province in 2010.
  • Establishment of Yangzhou Aidea Biotechnology Co., Ltd. (predecessor of Aidea Pharma)
Development program

Our strategy

Meeting needs in the field of HIV/AIDS treatment
Enhancing competitiveness in the field of urinary protein

Our strength

Accelerating drug innovation with rigorous scientific attitude
Generating stable cash flow from urinary protein business

  • 2009-2014
    Establishment of Aidea
  • 2015-2019
    Growth of Aidea
  • 2020-2024
    Fast development of Aidea
  • 2025-future
    Aidea in the leading position
Corporate culture
  • Our vision

    Evolving into a respectable and outstanding pharmaceutical company.

  • Our value

    Integrity       Accountability       Innovation       Perseverance

  • Our mission

    Dedicating for better medicine, pursuing greater success.